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Selective protein kinase inhibitors have only been
developed against a small number of kinase targets.
Here we demonstrate that ‘‘high-throughput kinase
profiling’’ is an efficient method for the discovery of
lead compounds for established as well as unex-
plored kinase targets. We screened a library of 118
compounds constituting two distinct scaffolds
(furan-thiazolidinediones and pyrimido-diazepines)
against a panel of 353 kinases. A distinct kinase
selectivity profile was observed for each scaffold.
Selective inhibitors were identified with submicro-
molar cellular activity against PIM1, ERK5, ACK1,
MPS1, PLK1-3, and Aurora A,B kinases. In addition,
we identified potent inhibitors for so far unexplored
kinases such as DRAK1, HIPK2, and DCAMKL1 that
await further evaluation. This inhibitor-centric
approach permits comprehensive assessment of
a scaffold of interest and represents an efficient
and general strategy for identifying new selective
kinase inhibitors.
INTRODUCTION
The success of Imatinib mesylate (Schiffer, 2007) as the first
small molecule targeted kinase inhibitor for use in cancer
therapy, validated protein kinases as important drug targets in
the treatment of human diseases (Cohen, 2002). The ubiquitous
presence of protein kinases in virtually all signal transduction
networks provides a clear impetus for the development of small
molecules that can modulate their activity. Indeed, protein868 Chemistry & Biology 18, 868–879, July 29, 2011 ª2011 Elsevier Lkinases along with G protein coupled receptors constitute the
most actively pursued classes of drug target. The protein kinase
family constitutes the largest gene-family ever to be tackled for
therapeutic development and hence there is an urgent need to
develop methodologies that will allow for the rapid discovery
and optimization of compounds that can both serve as pharma-
cological probes to validate the relevance of a particular kinase
as well as to serve as ‘‘lead’’ compounds for further drug devel-
opment activities. In addition, the majority of the kinome has not
been targeted with an inhibitor with a useful level of selectivity
and therefore there is a need to develop useful tool compounds
for these kinases.
Traditional kinase inhibitor discovery approaches have
concentrated on a single kinase at a time (Collins and Workman,
2006). These approaches usually involved performing a high-
throughput screen using biochemical and cellular assays
(Wesche et al., 2005), screening kinase-directed compound
libraries (Ding et al., 2002; Li et al., 2004), structure-guided
design (Dubinina et al., 2007), and fragment-based assembly
methods (Mu¨ller et al., 2010). In these methods, the initial
‘‘hits’’ are evolved using iterative rounds of structure-activity
relationship (SAR) guided optimization against a single kinase
target of interest. Selectivity and potency against other kinases
are assessed during the optimization process. As a result,
cross-reactivities against other kinases are only discovered
serendipitously. The most important drawback is that this tradi-
tional ‘‘linear’’ method of discovery has to be repeated for each
new kinase target of interest. There is no easy way to ascertain
the scope of a scaffold series against the entire kinome. These
target-driven methods are therefore low-throughput and time-
consuming.
Profiling inhibitor libraries against the entire enzyme class of
mammalian serine hydrolases has been recently shown with
great success (Bachovchin et al., 2010). A high-throughput
kinome-profiling of kinase-directed libraries has been proposedtd All rights reserved
X= S or NH
Y= O, NH or S
Z= furan or pyridine or
pyridone
X= H or Me
Figure 1. Chemical Scaffolds Explored in This Study
The hydrogen bond contacts to the kinase hinge region residues are marked
as dashed bonds.
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inhibitors (Goldstein et al., 2008). Kinome-profiling is
a ‘‘compound-centric’’ rather than target-centric method in
that it seeks to discover what the full range of kinase-targets
for a particular compound class are rather than simply what
compounds can target any particular kinase. Several assays
with a collection of kinases in a variety of formats have been
previously reported (Bain et al., 2007; Bantscheff et al., 2007;
Cohen, 2010; Fedorov et al., 2007; Karaman et al., 2008). With
steady technological improvements, several large scale kinase
screening campaigns employing large libraries of compounds
have been reported. In one study, 60 Ser/Thr kinases were
screened against 156 commercially available compounds
(Fedorov et al., 2007) whereas in another study, 577 compounds
of various chemical scaffolds were screened against 203 kinases
using the Ambit kinase platform (Bamborough et al., 2008). In
a most recent study, >20,000 compounds representing many
undisclosed structural classes were screened against 317–402
kinases in the ambit kinase platform (Posy et al., 2010). Many
of these methods were primarily used to annotate the selectivity
of established inhibitors rather than in a primary screening
approach to discover new inhibitors of established and novel
kinases. In this report, we demonstrate how high-throughput
kinome-profiling can be used to screen an entire library of 118
compounds against >60% of the human kinome thereby
providing a global survey of the utility of a particular chemical
scaffold. We utilized the largest kinase collection available at
Ambit Biosciences (353 kinase panel; http://www.kinomescan.
com/) to screen two unique scaffolds across the entire kinome.
Distinct examples from each scaffold were then biologically
characterized and developed as useful tool compounds for
PIM1, ERK5, ACK1, MPS1, PLK, and Aurora kinases.
RESULTS
Utilizing Novel Scaffolds for High-Throughput Kinase
Inhibitor Discovery
In this study, two type I kinase inhibitors scaffolds were explored
(Zhang et al., 2009). The first scaffold class were the furan thia-
zolidinediones that are type I inhibitors based on cocrystal struc-
tures with CDK2 kinase (Richardson et al., 2007) and Pi3Kg
kinase (Pomel et al., 2006). Crystallographic studies of these
compounds revealed that the thiazolidinedione group forms
hydrogen bonds to the catalytic lysine and aspartic acid of the
DFG motif thus achieving potent inhibition in the absence of
any hydrogen bonds to the kinase hinge-region. A similar coordi-
nation of the active site lysine is also found in complexes of the
glycocyamidine group in the natural product kinase inhibitor
Hymenialdisine (Meijer et al., 2000). In this report, we profiled
both furan thiazolidinediones that bind in type I fashion as well
as compounds that were designed to have the potential to
bind as type II (DFG-out) inhibitors (Liu andGray, 2006). (Figure 1;
see Table S4 available online for structures of compounds). The
second scaffold class were the pyrimidodiazepines that are type
I inhibitors that form a bidendate interactionwith the kinase hinge
using the pyrimidine ring nitrogen (N1) and the aniline NH (both
marked by dashed H-bonds in Figure 1) (Kwiatkowski et al.,
2010). The pyrimido diazepine scaffold described here was
originally derived from the PLK1 inhibitor BI 2536 (SteegmaierChemistry & Biology 18,et al., 2007) and BI-D1870 (Sapkota et al., 2007). The expansion
of the 6,6-ring system in BI 2536 to a 6,7-ring system to give rise
to pyrimido diazepines has been explored before as kinase inhib-
itors by us and others (Charrier and Durrant, 2010; Gray et al.,
2010). In this study, pyrimidodiazepines were explored as
a second scaffold series along with a set of pyrimido benzodiaz-
epines that were recently reported as inhibitors of ERK5 kinase
(Yang et al., 2010) (see Table S5 for structures of compounds).Kinome Spectrum and Selectivity
of the Thiazolidinedione-Type Compounds
The thiazolidinediones series were generated in a 2-4 step
process from readily available starting materials (see Supple-
mental Experimental Procedures for synthesis schemes). The
common chemical feature among all the compounds in this
series is the presence of the thiazolidinedione-like framework
at the 2 position of the furan. During the initial stages of this
study, other ‘‘head’’ groups such as the barbituric acid, thiobar-
bituric acid, creatinine, glycocyamidine (Wan et al., 2004),
pyrazolidinediones, indenediones, imidazolidinediones, and
thioimidazolidinones showed little or no interaction to the kinase
ATP site. Only the thiazolidinedione-like head groups, which
included the rhodanines and iminothiazolidinones showed
binding affinity to the ATP site. In general, the iminothiazolidi-
nones were more promiscuous kinase binders than the thiazoli-
dinediones followed by the rhodanines. At the 5-position of the
furan core, various substituted phenyl or naphthyl groups were
coupled using a Suzuki reaction. In certain cases, anilines were
appended to the benzoic acids through an amide linkage. In
total, 64 thiazolidinedione-type compounds (including both the
non-hinge binding furan-type compounds and the hinge-binding
pyridone-type compounds) were screened at 10 mM across
a 353-kinase panel. The primary screening data for the entire
collection of 64 compounds in this scaffold is available in Table
S4. About one-third of the total compounds in this set bound
strongly to DRAK1, HIPK1, and PIM2 kinases (Figure 2A) that
suggest that these kinases are likely to be the central targets
of this compound class. The primary Ambit screening data
were also clustered using the MultiExperiment Viewer (see
Experimental Procedures for more details). Clustering the
primary screening data provided an opportunity to correlate
structural features of the inhibitors and kinome selectivity. In
order to facilitate the analysis, an arbitrary cutoff score of 5%868–879, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 869
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Figure 2. Kinases Targeted by the Furan and Pyridone Thiazolidinone-Type Compounds
(A) Percent of kinases targeted by this scaffold (64 compounds) with an Ambit score of <1% of the DMSO control are highlighted in red circles. The size of the
circle represents the percentage of compounds that target a particular kinase. DRAK1 is themost highly targeted kinase with 28% followed by HIPK1 and PIM2 at
27%. Only targeted kinases of 10% and higher are indicated.
(B and C) The primary ambit data for all the (B) furan-type compounds and (C) pyridone-type compounds were clustered using MultiExperiment Viewer. Only
kinases with at least three compound hits and with a score of <5% of DMSO control were considered for this clustering analysis. Kinome Illustration reproduced
courtesy of Cell Signaling Technology (www.cellsignal.com).
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were chosen (Figures 2B and 2C). The less selective compounds
clustered separately to the left and pointed to functional groups
(such as an ortho-hydroxy functional group on the phenyl group
in compounds A50 and A23) that impart promiscuous recogni-
tion of the ATP-site through a putative hinge contact. A few
compounds with the furan core replaced with a phenyl, thiazole
or a pyridone core were also prepared. Whereas the phenyl core
compounds (A21 and A20) yielded few hits, the thiazole core
compound (A30), was less selective and less potent on a number
of targets. The hinge-binding pyridone compounds were clus-
tered separately as this small set of compounds exhibited
a slightly different spectrum of kinase targets (Figure 2C). This
set of pyridones was less selective than the non-hinge binding
furan compounds with overlapping targets of DRAK1, HIPK1,
and PIM2 in addition to new targets such as MSK2 (RPS6KA4)
and the DAPK family of kinases.
Furan Thiazolidinediones as PIM Kinase Inhibitors
The high-throughput kinase profiling revealed that the furan thia-
zolidinediones bound strongly to the PIM family of kinases.
In vitro biochemical assays were performed in parallel to deter-
mine themost potent tool compound (see Table S1 for SAR anal-870 Chemistry & Biology 18, 868–879, July 29, 2011 ª2011 Elsevier Lysis). Although a number of furan thiazolidinedione-like
compounds exhibited potent inhibition of PIM1 and PIM2 in
biochemical assays, many of the compounds with lower com-
puted logP values were not active in cellular assays presumably
due to poor membrane penetration (data not shown). We were
able to obtain compounds with robust cellular activity by
increasing the logP of the compounds. Compound A47 that
possessed an IC50 of 49 nM for inhibiting biochemical activity
of both PIM1 and PIM2 emerged as the most promising
compound from this set andwas chosen for further characteriza-
tion. Moreover, A47 is the first inhibitor that is equipotent on all
three isoforms of PIM kinase (Kd of 40, 23 and 13 nM on PIM
1, 2, and 3, respectively). In addition to binding potently to the
fingerprint kinases of this series, A47 also bound strongly to
other kinases like Aurora B (29 nM) and Aurora C (154 nM),
TGFBR4, and GAK kinases (Table 1; Figure S1A). Compounds
that possessed a putative hinge contact also targeted a subset
of these kinases. Following previous characterization of other
potential small molecule PIM kinase inhibitors (Pogacic et al.,
2007), the compound was characterized for its biological
activity. First, similar to the imidazo[1,2-b]pyridazine K00135,
A47 also significantly impaired survival of murine Ba/F3 cells
transformed to IL-3 independence by overexpression of PIM1td All rights reserved
Tab 1. Tool Compounds Elaborated from Each Scaffold
Com ound ID A47 A64 B46 B19 B B54
Stru ure
Key nase Kd (nM) PIM1: 40 HIPK2: 9.5 ERK5: 80 ACK1: 15 M 1: 26 Aur A/B/C: 
PIM2: 23
PIM3: 13
Key nase IC50 (nM) PIM1: 49 HIPK2: 74 ERK5:  ACK1:  M 1: 145 Aur A: 8
PIM2: 49 Aur B: 24
PIM3:  Aur C: 41
Off- gets (Kd/IC50) (nM) Aur B: 210/29 CSNK2A2: 6.1/ DCAMKL1: 97/ BRK: 37/47 G : 140/ TAOK2: /54.3
DAPK1: 9.5/
Aur C: /154 DYRK1A: 8.8/19 FRK: 96/264 P 1: 61/ MAP3K2: /155
DYRK1B: /62
MYLK4: 55/ HIPK2: 9.5/74 GAK: 270/ MAP3K3: /120
PIM3: 3.7/ TNK1: 110/
S(1 0.21 0.16 0.014 0.03 0 1 0.1
Too ompounds elaborated from each scaffold for PIM 1/2, HIPK2, ERK5, ACK1, MPS1, and Aurora kinases are shown. Kd and IC50 values for the ta t kinase and select off-target kinases are
indi ted. Selectivity scores (S(10)) for each compound were calculated as described before (Karaman et al., 2008). See also Figures S1–S6 for whole k e interaction map of the key compounds
as w ll as complete list of available Kds or IC50s.
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Figure 3. Cellular Data for the PIM1 Inhibitor A47
(A) Ba/F3 wild-type (WT) cells and stably expressing hPIM1 and/or hPIM2 cells were exposed to increasing amounts of A47 and cell viability was determined 24 hr
and 48 hr later (expressed as a percentage normalized to viability of cells treated with 0.1% DMSO only (n = 3). Data is shown for cell viability after 24 hr.
(B) MV4-11 cells were incubatedwith increasing concentrations of A47 for indicated times, harvested, and protein extracts separated by SDS-PAGE. The effect of
the compound on PIM endogenous target was followed by western blotting with indicated phospho-specific antibodies. Membranes were stripped and re-
probed with nonphospho-specific and anti-actin antibodies to check for equal loading.
(C) View of cocrystal structure between PIM1 kinase and furan thiazolidinedione A54. The inhibitor binds in a typical type I fashion and its trifluoromethylaniline
portion is directed toward the solvent exposed region.
Chemistry & Biology
High-Throughput Kinase Profilingor PIM2 (Figure 3A). Second, A47 impaired survival of a panel of
human acute leukemia cells that is associated with an impaired
phosphorylation of known PIM substrates such as 4EB-P1 in
a time- and dose-dependent fashion (Figure 3B; Figure S1B).872 Chemistry & Biology 18, 868–879, July 29, 2011 ª2011 Elsevier LMoreover, A47 also potentially blocked migration of Ba/F3 cells
overexpressing PIM1 toward CXCL12 gradient (Figure S1B),
demonstrating its inhibitory potential against PIM1 as this kinase
have been proposed to be a regulator of CXCR4 functiontd All rights reserved
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potential anticancer activities in part mediated by its activity
toward PIM1.We attempted to crystallize A47 but failed to obtain
diffraction quality crystals. The binding mode of a related furan
thiazolidinedione compound A54 that contained a ‘‘type II’’
chemical structure to induce a ‘‘DFG-out’’ conformation of the
activation loop was solved at 2.2 A˚ against PIM1 kinase (Fig-
ure 3C; see Table S6 for data collection and refinement statis-
tics). A54 is a weak inhibitor of PIM1/2 (IC50 of 774 and
814 nM, respectively) but possessed a much better selectivity
profile across the whole kinome than A47. In addition, A54 also
inhibited cell proliferation in PIM1 transformed Ba/F3 cells
(data not shown). However contrary to the design strategy, the
furan thiazolidinedione scaffold bound in a typical ‘‘type I’’
fashion to the PIM1 kinase with a conformation similar to the
inhibitors cocrystallized with Pi3Kg (Pomel et al., 2006) and
cdk2 (Richardson et al., 2007). The trifluoromethylaniline portion
of the inhibitor was partially visible in the electron density and
was directed to the solvent exposed region instead of toward
the hydrophobic pocket created by the DFG-out conformation
that is defining feature of a type II inhibitor. The inhibitor made
key hydrogen bond interactions between the nitrogen of the thia-
zolidinedione ring and the catalytic lysine K67 (3.0 A˚) as well as
the back bone NH of DFG aspartate D186 (3.6 A˚). The furan
and naphthyl rings made hydrophobic interactions with several
hydrophobic residues in the ATP site. The exocyclic carbonyl
made a weak interaction with the side chain of D186 (3.9 A˚).
We speculate that the replacement of this carbonyl with an imino
group (as in the lead PIM inhibitor A47) could afford extra stabi-
lization by interacting with the side chain of D186. A superim-
posed model of the lead inhibitor A47 on the PIM1/A54 complex
structure is included in the supplementary information
(Figure S1C).
Novel Inhibitors of HIPK1/HIPK2 Kinase
A structure-activity relationship study was performed in parallel
with high-throughput kinase profiling on a small set of
compounds from the pyridone thiazolidinediones (see Table
S2) using an in vitro biochemical assay by measuring inhibition
of immunoprecipitated HIPK2 activity as well as enzymatic IC50
values (SelectScreen kinase profiling assay) to determine the
most potent compounds. Compound A64 was the most potent
compound with an IC50 of 74 nM to emerge from this effort.
Because HIPKs have roles in cell cycle regulation (Iacovelli
et al., 2009; Trapasso et al., 2009), we decided that it was impor-
tant for a putative HIPK2 inhibitor not to influence Cdk1 activity.
The inhibition of the compounds on Cdk1 was also measured
using an in vitro MPF kinase assay (see Supplemental Experi-
mental Procedures). A64 was not an effective Cdk1 inhibitor
(IC50 > 10 mM). A64 was moderately selective across the
kinome (Table 1; Figure S2). Efforts to determine the on-target
cellular activity of the compound against HIPK2 were not
pursued as robust cellular assays to evaluate the role of this
kinase are not yet reported.
Kinome Spectrum and Selectivity of the Pyrimido
Diazepine and Benzodiazepine Compounds
A pyrimido diazepine and pyrimido benzodiazepine series was
synthesized from a 2,4-dichloropyrimidine (see SupplementalChemistry & Biology 18,Experimental Procedures for synthesis schemes). Various
members of pyrimido diazepines were generated by appending
different anilines at the C2 position of the pyrimidine as well as
introducing alkylated amides in the diazepine ring. In addition,
pyrimido benzodiazepines were synthesized by incorporating
an anthranilic acid into the 7-membered ring. In total, 52
compounds including 12 pyrimido benzodiazepines were
screened at 10 mM against a 353-kinase panel. The primary
screening data for the entire collection of 52 compounds in this
scaffold is available in Table S5. ERK5 (also known as BMK1),
PLK1 and 3, and DCAMKL1 and 2 were the most frequently
targeted kinases (Figure 4A; 10%–25% of the compounds). As
expected, based on the structural similarity to the BI-2536
PLK1,2,3 inhibitor, the pyrimido diazepines retained binding to
PLK1 and PLK3 (PLK2 not assayed) but several additional
kinases such as TTK (MPS1) and GAKwere targeted by a subset
of these compounds. In contrast, fusing an anthranilic acid to the
7-membered ring abolished binding to the PLK kinase family and
the other hits obtained for the pyrimido diazepines. Instead, the
most frequent targets of the pyrimido benzodiazepines were
ERK5 and DCAMKL1 and 2. The clustering data (Figure 4B)
clearly indicated the target cluster of the pyrimido benzodiaze-
pines separated from the diazepines. However, the target selec-
tivity of pyrimido benzodiazepines depends on certain distinct
structural features that are possessed only by a subset of
compounds. Pyrimido benzodiazepines such as B50 and B51
without aniline at the C2 of the pyrimidine did not display the
ERK5 and DCAMKL1 and 2 kinase target set. In addition,
compounds such as B48 and B49 with a reverse amide at the
C5 of the pyrimidine hit very few targets across the kinome.
Compounds with a bulky isopropoxy group at the ortho position
of the aniline attached to the C2 of the pyrimidine B23 lost
the pyrimido benzodiazepine target cluster activity. Similarly,
any substitution at this same position completely removed
activity against the Aurora kinases suggesting a low tolerance
for groups protruding toward the hinge region of the kinase
pocket. Methylation of the amide group controlled a tight
selectivity factor between the kinases TNK1 and ACK1 (also
known as TNK2) (B20 versus B19). Even though only a small
set of pyrimido benzodiazepines were profiled in this study
(12 compounds), selective and potent inhibitors were obtained
and characterized in detail for ERK5 (Yang et al., 2010), ACK1,
and Aurora kinases. In addition, a potent and selective pyrimido
diazepine inhibitor for MPS1/PLK1 (Kwiatkowski et al., 2010) is
also described.
Novel Inhibitors for ERK5 Kinase
A structure-activity guided optimization of compounds was per-
formed using a cellular ERK5 autophosphorylation assay (Deng
et al., 2011) in parallel with high-throughput kinase profiling.
Compound B46 was selected as the compound that displayed
the optimal combination of selectivity and cellular potency
(Yang et al., 2010). The whole kinome interaction map of B46
against a panel of 402 kinases indicated that B46 binds to only
four kinases with a score of <5% of DMSO control (Figure S3).
Kd determination confirmed the binding to ERK5 at 80 nM in
addition to DCAMKL1 (97 nM) and DCAMKL2 (190 nM) (Table 1).
From this data, itwasclear thatB46possesses remarkable selec-
tivity for ERK5 across the entire kinome with a Kd of <100 nM868–879, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 873
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Figure 4. Kinases Targeted by the Pyrimido Diazepines and Pyrimido Benzodiazepines
(A) Percent of kinases targeted by the pyrimido diazepines and pyrimido benzodiazepines with an Ambit score of <1% of DMSO control are highlighted in red
circles. The size of the circle represents the percentage a particular kinase is targeted. ERK5 is the most highly targeted kinase with 23% followed by PLK3 and
DCAMKL1 at 15%. Only targeted kinases of 8% and higher are indicated.
(B) The primary ambit data was clustered usingMultiExperiment Viewer. Only kinases with at least three compound hits and with a score of <5% of DMSO control
were considered for this clustering analysis. Kinome Illustration reproduced courtesy of Cell Signaling Technology (www.cellsignal.com).
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tested by inhibition of ERK5 autophosphorylation in HeLa cells
induced by EGF stimulation (Figure 5A) (Yang et al., 2010).
Novel Inhibitors for ACK1 Kinase
From the primary screening data, of the cluster of kinases that
were sensitive to the pyrimido benzodiazepine scaffold, only
ACK1 and GAK have a threonine as the gatekeeper (other
kinases such as TNK1 and ERK5 have a methionine as the gate-
keeper). This suggested an H-bond interaction between the
threonine side chain and the amide NH on the diazepine ring
that could be used as a filter to develop selective inhibitors for
ACK1. A homology model constructed using the X-ray crystal
structure of ACK1 with debromohymenialdisine (Lougheed
et al., 2004) also supported this observation. An SAR study
was performed by measuring the binding interaction of a series
of compounds against ACK1 using in vitro kinase assays
(SelectScreen Kinase Profiling Service) (data not shown; X.D.,
unpublished data). Compound B19 was the most potent and
selective compound among this series with a Kd of 15 nMagainst
ACK1 (Table 1; Figure S4). B19 was tested for inhibition of kinase
activity of ACK1 evaluated by monitoring EGF-induced auto-
phosphorylation in HEK293 cells (Figure 5B). The autophosphor-
ylation was abolished at 2 mM concentrations of B19 (lane 3)
whereas much less inhibitory effect was observed at 10 mM of
B20 (lane 4), a compound with methylated diazepine amide in874 Chemistry & Biology 18, 868–879, July 29, 2011 ª2011 Elsevier LB19, indicating that the diazepine amide in B19 determines the
binding specificity to ACK1. Interestingly cotransfection of
a GTPase defective mutant of Cdc42, Cdc42Q61L, which acti-
vates ACK1 kinase, recovered part of inhibitory effect of B19
(compare lane 7 with lane 3), suggesting that either Cdc42
competes with the binding site of B19 or Cdc42 caused ACK
conformational change that reduces the binding affinity to B19.
Furthermore, we also tested the effect of B19 on lung cancer
A549 cell growth (Figure 5C). At 10 mM, B19 completely inhibited
the cancer cell growth, and partially inhibited EGF-stimulated
cancer cell growth.
Novel Dual Inhibitors of MPS1 and PLK1 Kinases
MPS1 emerged as a novel target for the 7-membered ring
expanded versions of the dihydropteridinones BI-2536 and
BI-D1870 in addition to maintaining reasonable potency against
PLK1. A structure-activity relationship study of compounds was
performed using in vitro kinase assays (SelectScreen Kinase
Profiling Service) in parallel with high-throughput kinase profiling
(see Table S3). Compound B13 was selected as the compound
that displayed the desired combination of selectivity and
potency for MPS1 (Kwiatkowski et al., 2010). The whole kinome
interaction map of B13 against a panel of 402 kinases indicated
that B13 binds to only 4 kinases with a score of <5% of DMSO
control (Figure S5). Kd determination confirmed the binding to
MPS1 at 12 nM in addition to PLK1 (61 nM) and GAK (140 nM)td All rights reserved
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Figure 5. Cellular Data of the ERK5 Inhibitor B46 and ACK1 Inhibitor B19
(A) HeLa cells were serum starved overnight followed by treatment with different concentrations of B46 for 1 hr. Cells were then stimulated with EGF for 17min and
BMK1 activation was detected by mobility retardation.
(B) ACK1 or TNK1 cDNA in pcDNA3 vector was transfected into HEK293 cells for 36 hr. DMSO (control), B19 or B20 (N-Me amide version) at indicated
concentration was added into the culture medium for 12 hr. The cells were lysed and the cell lysates were subjected to SDS-PAGE. Tyrosine phosphorylated ACK
was detected by immunoblotting with anti-phosphotyrosine antibody (4G10).
(C) A549 cells were seeded in a 6-well culture plate at a density of 2000/well. EGF (50 ng/ml), AG1478 (1 mM), B19 (10 mM), or DMSO (control) was added into
culture medium and refreshed every 3 days. The cells were cultured for 7 days and the number of cells was counted with Bright-Line Hemacytomer (Hausser
Scientific) under microscope.
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primary screening at 10 mM with Flt3 was not confirmed. From
this data, it was clear that B13 possesses remarkable selectivity
for MPS1 and PLK1 across the entire kinome with a Kd of
<100 nM for only the 2 of 402 kinases tested. The cellular activity
of B13 onMPS1was tested by assessing the compound’s ability
to inactivate the spindle assembly checkpoint (SAC), the activity
of which requires MPS1 kinase activity (Figures 6A and 6B).
Degradation of cyclin B can be used to monitor the progress of
the cell throughmitosis. The levels of cyclin B accumulate during
G2 phase and sustain in the presence of an activated SAC. In
U2OS cells, a dose-dependent drop in cyclin B levels was
observed in the presence of B13 that could be reversed by the
addition of the proteasome inhibitor MG132 (Figure 6B).
Novel Inhibitors Targeting Aurora Kinases
Intracellular screening of a select set of pyrimido benzodiaze-
pines identified compounds having SAC inhibitory activity as
assessed by the ability of the compounds to bypass a Taxol-
induced mitotic arrest. Profiling of these compounds against
a panel of 402 kinases showed that they lacked activity against
MPS1, a checkpoint kinase targeted by the pyrimido diazepineChemistry & Biology 18,B13. This result was consistent with existing SAR data of these
compounds that demonstrated that substitutions at positions
a, b to the carbonyl moiety abolished the ability to inhibit
MPS1. Compound B54 was shown to have SAC inhibitory
activity at concentrations as low as 50 nM (Figure S6B). Further
inspection of the profiling data revealed a modest Ambit binding
score for B54 against Aurora B (primary screening score of 1.4 at
1 mMscreening; Figure S6A for whole kinome interaction map for
B54). Subsequent in vitro kinase assays supported this assertion
demonstrating that B54 had biochemical IC50 of 8 nM, 24 nM,
and 41 nM for Aurora A, B, and C, respectively (Table 1). Treat-
ment of U2OS cells with B54 demonstrated a dose-dependent
decrease in Aurora A and B autophosphorylation and of Histone
H3 ser10 phosphorylation, a known substrate for Aurora B
(Figure 6C). At concentrations of 250 nM and above, the forma-
tion of monopolar spindles was observed, an indicator of Aurora
A inhibition (Figure S6B).
DISCUSSION
Traditional kinase inhibitor discovery is a low-throughput
process not optimized to efficiently annotate the inhibitory868–879, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 875
A C
B
Figure 6. Cellular Data of the Dual MPS1/Polo-Like Kinases Inhibitor B13 and Pan-Aurora Kinase Inhibitor B54
(A) Schematic of the treatment regimen used to assess the effect of B13 treatment on spindle checkpoint-induced mitotic arrest in U2OS cells.
(B) Immunoblot of cyclin B from U2OS cells treated with B13. U2OS cells were arrested in mitosis by combination treatment of thymidine and nocodazole prior to
treatment with nocodazole or coadministration with B13 ± MG132 for 2 hr.
(C) Immunoblot ofmitotic markers fromU2OS cells treatedwith B54. U2OS cells were arrested inmitosis by combination treatment of thymidine and Taxol prior to
treatment with Taxol or coadministration with B54 (or VX-680) ± MG132 for 2 hr.
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High-Throughput Kinase Profilingpotential of a given scaffold against the entire kinome. In addi-
tion, the vast majority of kinase inhibitor discovery efforts takes
place in the pharmaceutical industry and predominantly focuses
on well-established kinase targets. Thus, despite the tremen-
dous investments in making new kinase inhibitors, the majority
of kinases are still not targeted with an inhibitor with a useful level
of selectivity. In order to address this problem, we explored the
potential of a high-throughput kinase profiling strategy to rapidly
deliver new kinase inhibitors. We chose to investigate two chem-
ical scaffold classes that were previously underexplored in detail
as kinase inhibitors. Distinct hits from each of the scaffold series
were obtained for established as well as novel kinase targets.
Most importantly, tool compounds were elaborated for six
different kinases to validate the utility of the high-throughput
kinase profiling method. These tool compounds meet the criteria
for a chemical probe in order to investigate the activity of
a desired kinase of interest (Frye, 2010; Kodadek, 2010). In addi-
tion, valuable leads were obtained for established and novel
kinases such as DRAK1/2, and DCAMKL1/2 that await further
characterization. In this study, one example for the furan thiazo-
lidinediones was characterized in detail as an inhibitor of the PIM
kinases. The PIM kinases are attractive targets for targeted
cancer therapy as they are aberrantly expressed in prostate
cancer and other hematological malignancies (Brault et al.,
2010). Many recent publications have detailed the discovery
and application of PIM kinase inhibitors (Akue´-Ge´du et al.,
2010; Brault et al., 2010; Chang et al., 2010; Lo´pez-Ramos
et al., 2010; Sliman et al., 2010; Tao et al., 2009). The furan thia-
zolidinedione PIM kinase inhibitors reported here share the
thiazolidinedione-like pharmacophore with the benzylidene thia-
zolidinediones (Xia et al., 2009). The PIM inhibitor characterized876 Chemistry & Biology 18, 868–879, July 29, 2011 ª2011 Elsevier Lin this report A47, is potent against all three PIM kinases and
displays on-target cellular activity (Figures 3A and 3B). Even
though A47 displays only moderate selectivity across the entire
kinome, it demonstrates the utility of high-throughput kinase
profiling for identifying lead compounds that can be subject to
furthermedicinal chemistry efforts. Based on the cocrystal struc-
ture of PIM1 with compound A54 (Figure 3C), the increased
promiscuity of the lead PIM inhibitor A47 can be speculated to
be due to a possible hinge contact between the backbone NH
of the kinase hinge region residues and the isoquinoline nitrogen
of the inhibitor. An example from the pyridone thiazolidinediones
was elaborated through in vitro biochemical assays as an inhib-
itor for HIPK2 (homeodomain-interacting protein kinase 2).
HIPK2 is a Ser-Thr kinase with important roles in cell growth
and apoptosis in various cell types, tissues and organisms (Cal-
zado et al., 2007; Rinaldo et al., 2007). HIPK2 has been shown to
be a potential tumor suppressor as well as a DNA-damage
response modulating kinase by activating the apoptosis
pathway through phosphorylation of downstream targets
including the tumor suppressor p53 (Puca et al., 2010). Selective
and potent inhibitors for HIPK2 are thus extremely valuable in
delineating the myriad roles played by HIPK2. We chose to
develop tool compounds for a novel kinase such as HIPK2 as
no inhibitors are currently available. Inhibitors of other kinases
have been shown to cross-react with HIPK2 in a profiling study
of Ser-Thr kinases (Bain et al., 2007). The high-throughput
profiling method described here was valuable to discover impor-
tant leads as HIPK2 inhibitors that can be used to interrogate
HIPK2 function in cellular experiments. Unfortunately, we were
unable to characterize the ability of A64 to target HIPK2 in cells
due to a lack of a relevant functional assay. Examples fromtd All rights reserved
Chemistry & Biology
High-Throughput Kinase Profilingboth the pyrimido diazepines and pyrimido benzodiazepines
were characterized in detail as inhibitors for ERK5, ACK1,
MPS1/PLK1, and Aurora A/B. Mitogen-activated protein kinases
(MAPKs) are well known to be involved in modulating cellular
function and are recognized as important targets in the treatment
of cancer (Montagut and Settleman, 2009). The characterization
of the detailed biological functions of ERK5 has been hampered
by the lack of a potent and selective small molecule ERK5 inhib-
itor. Recently, a dual MEK5/ERK5 inhibitor has been reported
from the indolinone carboxamide class (Tatake et al., 2008). In
our study, detailed SAR done in parallel with high-throughput
kinome profiling yielded compound B46 as a selective ERK5
inhibitor with potent cellular inhibition of ERK5 autophosphoryla-
tion. B46 was used as a pharmacological inhibitor to validate the
tumorigenic role of ERK5 and showed efficacy in murine xeno-
graft models (Yang et al., 2010). ACK1 (activated Cdc42 associ-
ated kinase also known as TNK2) is a nonreceptor tyrosine
kinase and overexpression of ACK1 has been found to correlate
with increased invasive phenotype of cancer cells and predispo-
sition of primary tumor cells to metastasis (van der Horst et al.,
2005). In addition, activated ACK1 was found to promote pros-
tate cancer progression by androgen receptor phosphorylation
(Mahajan et al., 2007). Thus, selective and potent inhibitors of
ACK1 are useful in probing the role of ACK1 in cancer. Pyrazolo
pyrimidines and Lck kinase inhibitors have been reported as
potent ACK1 inhibitors (DiMauro et al., 2007; Kopecky et al.,
2008). In our study, detailed SAR supported by the speculated
interaction between the diazepine ring amide and the gate-
keeper threonine, led to compound B19 as the most potent
and selective compound for ACK1. B19 is also one of the most
selective kinase inhibitors reported with a measured Kd of
<50 nM against only two kinases across the entire kinome.
MPS1 (or TTK) is a dual specificity kinase that plays an important
role in ensuring the fidelity of mitosis and its role in the spindle
assembly checkpoint (SAC) (Musacchio and Salmon, 2007). A
selective small molecule inhibitor of MPS1 is useful in probing
the function of MPS1 as well as a potential use in cancer drug
discovery targeting mitotic kinase signaling pathways. Prior to
the disclosure of compound B13 (Kwiatkowski et al., 2010), there
were two MPS1 small molecule inhibitors reported in the litera-
ture (Dorer et al., 2005; Schmidt et al., 2005). In this report,
high-throughput kinase profiling along with detailed SAR study
led to B13 as the most potent and selective MPS1 inhibitor
reported thus far. B13 was used to describe the role of MPS1
kinase activity in establishment and maintenance of the SAC
and investigate the potential therapeutic value of pharmacolog-
ical targeting of the SAC (Kwiatkowski et al., 2010 and unpub-
lished work). The human Aurora family of kinases includes three
closely related protein kinases Aurora A, B, and C. Each kinase is
cell cycle regulated and shows hyperactivation in mitotic cells,
but they show distinct localization and functions. In this report,
biochemical and intracellular investigation revealed a pyrimido
benzodiazepine, B54, to be a potent and selective pan-Aurora
kinase small molecule inhibitor. Currently, it remains to be seen
whether a selective Aurora A, B, or C inhibitor can be attained
based on this scaffold class. Compounds selective for particular
Aurora family kinases have been vital to assessing the thera-
peutic benefit gained from selective pharmacological inactiva-
tion of the individual Aurora kinases.Chemistry & Biology 18,SIGNIFICANCE
Many kinase inhibitor development programs consist of
optimizing previously known kinase inhibitors that were
serendipitously discovered to possess activity toward
a new kinase-target of interest. High-throughput kinome
profiling is an efficient way to discover inhibitors by
screening compounds against the entire kinome. Here we
have demonstrated that by applying kinome-wide profiling
at initial screening-stage one can efficiently annotate all
the potential kinase targets for a given scaffold-class of
interest. One major advantage of this approach is it circum-
vents the need to develop and implement a new high-
throughput screening campaign for each new kinase of
interest. Once the potential kinase binding partners are
identified, appropriate enzymatic and cellular assays must
be developed to verify whether bona fide inhibitors have
been obtained andwhat the effective cellular concentrations
of the inhibitor might be. This is especially true when the
broad screen is done at a single high concentration of
10 mM and the resulting binding score has only qualitative
correlation with what might be an effective cellular concen-
tration of the inhibitor. We have applied this strategy to two
different scaffold classes to obtain the kinome wide targets
for the furan thiazolidinediones and pyrimido diazepines and
have discovered nanomolar to single digit micromolar
cellular inhibitors of PIM2, ERK5, ACK1, MPS1, PLK1, and
Aurora kinases. Several other potential targets of the inhib-
itors including DAPK1, DRAK1, and HIPK2 await additional
cellular studies. We anticipate that continued application
of this approach with diverse ATP-site directed templates
will deliver new inhibitors for the majority of the kinome
that is still not targeted with inhibitors of useful levels of
selectivity.EXPERIMENTAL PROCEDURES
Compounds Preparation and Screening on Ambit Kinase Platform
All compounds were dissolved and stored at 20C as DMSO stocks.
Compounds were screened at a single concentration of 10 mM using binding
assays as described previously (Fabian et al., 2005; Wodicka et al., 2010).
Briefly, extracts containing kinases (expressed either as T7 phage fusion
proteins or DNA-tagged) are incubated with an immobilized bait compound
(known inhibitor like staurosporine) and the test compound (at 10 mM). Test
compounds that displace the immobilized bait compound are detected by
quantitative PCR. The results are expressed as the percentage of kinase
bound to the bait compound bead relative to a DMSO control (%control).
Compounds with high affinity have %control of 0–1 whereas compounds
with lower affinity have higher scores. As false positives (and negatives) are
observed in single-point concentration assays, it is important to confirm
a high affinity interaction by determining the Kd of binding. Because the deter-
mination of the Kds of all compound-kinase pairs is not practical, only Kds for
the most important and relevant ones were tested. Even though the kinome-
wide hits analysis was performed only with primary screening data and not
with Kd data, good correlation has been observed by comparison of Kd data
to single concentration results for a given kinase (Bamborough et al., 2008).
Clustering Data
The primary ambit data was clustered using Multiexperiment viewer v4.3
(http://www.tm4.org/mev.html). Hierarchical clustering was done using the
following parameters: (1), both the compound IDs and the kinases were clus-
tered; (2), ordering of the leaves were optimized for both the compound IDs as868–879, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 877
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High-Throughput Kinase Profilingwell as kinases; (3), the default distance metric (Euclidean) was chosen; and
(4), average linkage method was used to indicate the cluster to cluster
distances.
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Coordinates have been deposited in the Protein Data Bank with accession
code 3QF9.
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